Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
The members of inhibitor of apoptosis proteins (IAPs) family are key negative regulators of apoptosis. Overexpression of IAPs are found in hepatocellular carcinoma (HCC), and can contribute to chemotherapy resistance and recurrence of HCC. Small-molecule Second mitochondria-derived activator of casp...
Main Authors: | Shuijun Zhang, Gongquan Li, Yongfu Zhao, Guangzhi Liu, Yu Wang, Xiuxian Ma, Dexu Li, Yang Wu, Jianfeng Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3519882?pdf=render |
Similar Items
-
Targeting apoptotic machinery as approach for anticancer therapy: Smac mimetics as anticancer agents
by: Nevine M.Y. Elsayed, et al.
Published: (2015-06-01) -
Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines
by: Annkathrin Koch, et al.
Published: (2021-05-01) -
Future Therapeutic Directions for Smac-Mimetics
by: Emma Morrish, et al.
Published: (2020-02-01) -
Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms
by: Dae-Sun Kim, et al.
Published: (2017-08-01) -
The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma
by: Zide Chen, et al.
Published: (2018-11-01)